Indeed, there are several cancer drugs approved by FDA, such as 5-azacytidine and decitabine that act as DNA methyltransferase (DNMT) inhibitors or SAHA and romidepsin that act as histone deacetylase (HDAC) inhibitors (Rius and Lyko, 2012). This evidence concerns the gene HDAC9 and cancer.